abiraterone has been researched along with dehydroepiandrosterone in 9 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (dehydroepiandrosterone) | Trials (dehydroepiandrosterone) | Recent Studies (post-2010) (dehydroepiandrosterone) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 10,043 | 639 | 1,826 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Balk, SP; Bubley, GJ; Cai, C; Chen, S; Marck, B; Matsumoto, AM; Mostaghel, EA; Nelson, PS; Ng, P; Simon, NI; Wang, H | 1 |
| Chen, HL; Du, JJ; Li, YC | 1 |
| Labrie, F | 1 |
| Adomat, H; Deb, S; Gleave, M; Guns, ES; Hosseini-Beheshti, E; Ming, DS; Pham, S; Zoubeidi, A | 1 |
| DeVore, NM; Petrunak, EM; Porubsky, PR; Scott, EE | 1 |
| Bansal, S; Lau, AJ; Wong, SY; Yip, CKY | 1 |
| Carthon, B; Chiong, E; Figg, WD; Fishkin, P; Harvey, RD; Ibraheem, A; Karrison, T; Kozloff, MF; Martinez, E; Nabhan, C; Peer, CJ; Ratain, MJ; Stadler, WM; Szmulewitz, RZ; Yong, WP | 1 |
| Chai, CLL; Chan, ECY; Cheong, EJY; Chiong, E; Esuvaranathan, K; Fan, H; Figg, WD; Lin, F; Miners, JO; Nair, PC; Neo, RWY; Peer, CJ; Szmulewitz, RZ; Tu, HT | 1 |
| Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Li, PK; Liu, C; Liu, L; Lombard, AP; Lou, W; Ning, S; Yang, JC; Zhao, J; Zhao, R | 1 |
2 review(s) available for abiraterone and dehydroepiandrosterone
| Article | Year |
|---|---|
[Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents; Dehydroepiandrosterone; Dihydrotestosterone; Enzyme Inhibitors; Humans; Male; Molecular Structure; Pregnenolone; Progesterone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2013 |
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamides; Dehydroepiandrosterone; Endocrinology; Gonadotropin-Releasing Hormone; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone; Treatment Outcome | 2015 |
1 trial(s) available for abiraterone and dehydroepiandrosterone
| Article | Year |
|---|---|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Fasting; Food; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Singapore; Testosterone; Treatment Outcome; United States | 2018 |
6 other study(ies) available for abiraterone and dehydroepiandrosterone
| Article | Year |
|---|---|
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Dehydroepiandrosterone; Female; Humans; Indomethacin; Male; Mice; Orchiectomy; Pregnenolone; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Up-Regulation | 2011 |
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Azasteroids; Cell Line, Tumor; Dehydroepiandrosterone; Dutasteride; Humans; Kallikreins; Progesterone; Prostate-Specific Antigen; Receptors, Androgen | 2014 |
Structures of human steroidogenic cytochrome P450 17A1 with substrates.
Topics: 17-alpha-Hydroxyprogesterone; Androstenes; Androstenols; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Dehydroepiandrosterone; Estrogens; Heme; Humans; Hydrogen Bonding; Kinetics; Models, Molecular; Molecular Structure; Mutation; Oxidation-Reduction; Pregnenolone; Progesterone; Protein Binding; Protein Structure, Secondary; Steroid 17-alpha-Hydroxylase; Steroids; Substrate Specificity; Testosterone | 2014 |
Identification of Galeterone and Abiraterone as Inhibitors of Dehydroepiandrosterone Sulfonation Catalyzed by Human Hepatic Cytosol, SULT2A1, SULT2B1b, and SULT1E1.
Topics: Adolescent; Adult; Aged; Androstadienes; Androstenes; Benzimidazoles; Cytosol; Dehydroepiandrosterone; Female; Humans; Kinetics; Liver; Male; Middle Aged; Sulfotransferases; Young Adult | 2018 |
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Topics: Androstenes; Cell Line, Tumor; Dehydroepiandrosterone; Enzyme Inhibitors; Humans; Kinetics; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Steroids | 2020 |
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Benzamides; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; RNA-Seq; Steryl-Sulfatase | 2020 |